Research Assistant Professor of Neurological Surgery
Pediatric gliomas are among the most formidable and devastating cancers in children. Surgery followed by radio- and/or chemotherapy is often ineffective due to chemo- and/or radio-resistance. Our research is focusing on the role of posttranslational histone protein modifications in therapeutic resistance.
Ann & Robert H. Lurie Children’s Hospital of Chicago
Targeting histone H3K4me3 for the treatment of pediatric gliomas
Pediatric high-grade gliomas (pHGGs) are a fatal childhood cancer of the brain. Deregulation of specific histone modifications, both with and without a direct link to specific mutations, have been identified in these tumors. This project will investigate histone H3 post-translational modifications (PTMs) in pHGGs to advance our understanding of tumor development and understanding of biologic characteristics, and to promote the identification of effective therapies for improving the outcomes for patients with these tumors.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test